Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone- sulphate in first-episode schizophrenia: Relationship to gender, aggression and symptomatology

Schizophrenia Research

Volumn 71, Issue 2-3, 2004, Pages 427-434

  Strous, Rael D ^a,b   Maayan, Rachel ^b   Lapidus, Raya ^a   Goredetsky, Leonid ^a   Zeldich, Ella ^b   Kotler, Moshe ^a,b   Weizman, Abraham ^b,c  

^a BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

DHEA; DHEA S; First episode schizophrenia

Indexed keywords

HYDROCORTISONE; NEUROSTEROID; PRASTERONE; PRASTERONE SULFATE;

ADULT; AGGRESSION; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HOSPITALIZATION; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

ADULT; AGGRESSION; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEX FACTORS;

EID: 4944263865     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.03.005     Document Type: Article

References (43)

1. Akwa Y., Baulieu E.E. Dehydroepiandrosterone sulfate and dehydroepiandrosterone: neuroactive neurosteroids. Curr. Opin. Endocrinol. Diabetes. 7:2000;160-167
2. Barry N.N., McGuire J.L., van Vollenhoven R.F. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels and clinical response. J. Rheumatol. 28:1998;2352-2356
3. Baulieu E.E., Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J. Endocrinol. 150:1996;S221-S239. (Suppl.)
4. Bloch M., Schmidt P.J., Danaceau M.A., Adams L.F., Rubinow D.R. Dehydroepiandrosterone treatment of midlife dysthymia. Biol. Psychiatry. 45:1999;1533-1541
5. Coccaro E.F., Berman M.E., Kavoussi R.J. Assessment of life history of aggression: development and psychometric characteristics. Psychiatry Res. 73:1997;147-157
6. Corpechot C., Robel P., Axelson M., Sjovall J., Baulieu E.E. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc. Natl. Acad. Sci. U. S. A. 78:1981;4704-4707
7. Demirgoren S., Majewska M.D., Spivak C.E., London E.D. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABA-A receptor. Neuroscience. 45:1991;127-135
8. Erb J.L., Kadane J.B., Tourney G., Mickelsen R., Trader D., Szabo R., Davis V. Discrimination between schizophrenic and control subjects by means of plasma dehydroepiandrosterone measurements. J. Clin. Endocrinol. Metab. 52:1981;181-186
9. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), Version 2. 1994;New York State Psychiatric Institute, Biometrics Research, New York
10. Friess E., Schiffelholz T., Steckler T., Steiger A. Dehydroepiandrosterone - a neurosteroid. Eur. J. Clin. Invest. 30(Suppl. 3):2000;46-50
11. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. 1976;218-222 National Institute of Mental Health, Rockville, MD
12. Hamilton M. The assessment of anxiety scales by rating. Br. J. Psychol. 32:1959;50
13. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62
14. Harris D.S., Wolkowitz O.M., Reus V.I. Movement Disorder, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J. Biol. Psychiatry. 2:2001;99-102
15. Herbert J. Neurosteroids, brain damage, and mental illness. Exp. Gerontol. 33:1998;713-727
16. Hu Y., Cardounel A., Gursoy E., Anderson P., Kalimi M. Anti-stress effects of dehydroepiandrosterone: protection of rats against repeated immobilization stress-induced weight loss, glucocorticoid receptor production, and lipid peroxidation. Biochem. Pharmacol. 59:2000;753-762
17. Johnson M.D., Bebb R.A., Sirrs S.M. Uses of DHEA in aging and other disease states. Ageing Res. Rev. 1:2002;29-41
18. Kay S., Fiszbein A., Opler L.A. The positive and negative syndrome scale for schizophrenia. Schizophr. Bull. 13:1987;261-276
19. Kroboth P.D., Salek F.S., Pittenger A.L., Fabian T.J., Frye R.F. DHEA and DHEA-S: a review. J. Clin. Pharmacol. 39:1999;327-348
20. Maayan R., Yagorowski Y., Grupper D., Weiss M., Shtaif B., Kaoud M.A., Weizman A. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol. Psychiatry. 48:2000;693-701
21. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABA-A receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38:1992;379-395
22. Miczek K.A., Fish E.W., De Bold J.F. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm. Behav. 44:2003;242-257
23. Monteleone P., Luisi M., Colurcio B., Casarosa E., Monteleone P., Ioime R., Genazzani A.R., Maj M. Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa. Psychosom. Med. 63:2001;62-68
24. Morales A.J., Nolan J.J., Nelson J.C., Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78:1994;1360-1367
25. Oberbeck R., Benschop R.J., Jacobs R., Hosch W., Jetschmann J.U., Schurmeyer T.H., Schmidt R.E., Schedlowski M. Endocrine mechanisms of stress-induced DHEA-secretion. J. Endocrinol. Invest. 21:1998;148-153
26. Oertel G.W., Benes P., Schirazi M., Holzmann H., Hoffmann G. Interaction between dehydroepiandrosterone, cyclic adenosine-3′,5′-monophosphate and glucose-6-phosphate-dehydrogenase in normal and diseased subjects. Experientia. 30:1974;872-873
27. Orentreich N., Brind J.L., Rizer R.L., Vogelman J.H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59:1984;551-555
28. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J. 6:1992;2311-2322
29. Ritsner, M., Maayan, R., Gibel, A., Strous, R.D., Modai, I., Weizman, A., In press. Elevation of the cortisol/dehydroepiandrosterone and cortisol/dehydroepiandrosterone sulfate ratios in medicated schizophrenia inpatients. Europ. Neuropsychopharm.
30. Rosenfeld R.S., Rosenberg B.J., Fukushima D.K., Hellman L. 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. Clin. Endocrinol. Metab. 40:1975;850-855
31. Rupprecht R., di Michele F., Hermann B., Strohle A., Lancel M., Romeo E., Holsboer F. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res. Rev. 37:2001;59-67
32. Sondergaard H.P., Hansson L.O., Theorell T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: findings from a longitudinal study of refugees in Sweden. Psychother. Psychosom. 71:2002;298-303
33. Spivak B., Maayan R., Kotler M., Mester R., Gil-Ad I., Shtaif B., Weizman A. Elevated circulatory level of GABA-A-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol. Med. 30:2000;1227-1231
34. Strous R.D., Spivak B., Yoran-Hegesh R., Maayan R., Averbuch E., Kotler M., Mestor R., Weizman A. Analysis of neurosteroid levels in attention deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 4:2001;259-264
35. Strous R.D., Maayan R., Lapidus R., Stryjer R., Lustig M., Kotler M., Weizman A. Value of dehydroepiandrosterone (DHEA) augmentation in the management of negative symptoms in schizophrenia. Arch. Gen. Psychiatry. 60:2003;133-141
36. Tamminga C.A. Gender and schizophrenia. J. Clin. Psychiatry. 58(Suppl. 15):1997;33-37
37. Tourney G., Erb J.L. Temporal variations in androgens and stress hormones in control and schizophrenic subjects. Biol. Psychiatry. 14:1979;395-404
38. Tourney G., Hatfield L. Plasma androgens in male schizophrenics. Arch. Gen. Psychiatry. 27:1972;753-755
39. Wen S., Dong K., Onolfo J.P., Vincens M. Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. Eur. J. Pharmacol. 430:2001;373-374
40. Wolf O.T., Neumann O., Hellhammer D.H., Geiben A.C., Strasburger C.J., Dressendorfer R.A., Pirke K.M., Kirschbaum C. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J. Clin. Endocrinol. Metab. 82:1997;2363-2367
41. Wolkowitz O.M., Reus V.I., Roberts E., Manfredi F., Chan T., Raum W.J., Ormiston S., Johnson R., Canick J., Brizendine L., Weingartner H. Dehydroepiandrosterone (DHEA) treatment of depression. Biol. Psychiatry. 41:1997;311-318
42. Wolkowitz O.M., Reus V.I., Keebler A., Nelson N., Friedland M., Brizendine L., Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry. 156:1999;646-649
43. Young A.H., Gallagher P., Porter R.J. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am. J. Psychiatry. 159:2002;1237-1239